Abstract
Background Brain structure abnormalities throughout the course of Parkinson’s disease (PD) have yet to be fully elucidated. Inconsistent findings across studies may be partly due to small sample sizes and heterogeneous analysis methods. Using a multicenter approach and harmonized analysis methods, we aimed to overcome these limitations and shed light on disease stage-specific profiles of PD pathology as suggested by in vivo neuroimaging.
Methods Individual brain MRI and clinical data from 2,367 PD patients and 1,183 healthy controls were collected from 19 sites, deriving from 20 countries. We analyzed regional cortical thickness, cortical surface area, and subcortical volume using mixed-effect linear models. Patients were grouped according to the Hoehn & Yahr (HY) disease stages and compared to age- and sex-matched controls. Within the PD sample, we investigated associations between Montreal Cognitive Assessment (MoCA) scores and brain morphology.
Findings The main analysis showed a thinner cortex in 38 of 68 regions in PD patients compared to controls (dmax = −0·25, dmin = −0·13). The bilateral putamen (left: d = −0·16, right: d = −0·16) and left amygdala (d = −0·15) were smaller in patients, while the left thalamus was larger (d = 0·17). HY staging indicated that a thinner cortex initially presents in the occipital, parietal and temporal cortex, and extends towards caudally located brain regions with increased disease severity. From HY stage 2 and onwards the bilateral putamen and amygdala were consistently smaller with larger effects denoting each increment. Finally, we found that poorer cognitive performance was associated with widespread cortical thinning as well as lower volumes of core limbic structures.
Interpretation Our findings offer robust and novel imaging signatures that are specific to the disease severity stages and in line with an ongoing neurodegenerative process, highlighting the importance of such multicenter collaborations.
Funding NIH Big Data to Knowledge program, ENIGMA World Aging Center, and ENIGMA Sex Differences Initiative, and other international agencies (listed in full in the Acknowledgments).
Competing Interest Statement
K.L.P. reports honoraria from invited scientific presentations to universities and professional societies not exceeding $5,000/yr, is reimbursed by Sanofi, AstraZeneca, and Sangamo BioSciences for the conduct of clinical trials, has received consulting fees from Allergan and Curasen, and is funded by grants from the Michael J Fox Foundation for Parkinson's Research and the NIH. R.M.A.D.B. received unrestricted research grants from Medtronic, GEHealth, Lysosomal Therapeutics, all paid to the Institution. R.H. serves on the Clinical Advisory Board of Cadent Therapeutics. O.A.v.d.H received funding for a honorarium lecture from Benecke. C.T.M. receives research funding from Biogen, Inc and provides consulting services for Invicro and Axon Advisors on behalf of Translational Bioinformatics, LLC. He also receives an honorarium as Associate Editor of NeuroImage: Clinical. N.J. and P.M.T. received partial grant support from Biogen, Inc., for research unrelated to the topic of this manuscript. None of the other authors declares any competing financial interests.
Clinical Protocols
http://enigma.ini.usc.edu/protocols/imaging-protocols/
Funding Statement
ENIGMA Core: This work was supported in part by NIH grants R56AG058854, R01AG059874, R01MH116147, R01MH117601, U54EB020403, and the Michael J Fox Foundation grant 14848, and the Kavli Foundation Neurodata without Borders PPMI: Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit www.ppmi-info.org. PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including AbbVie, Allergan, Amathus Therapeutics, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, Janssen Neuroscience, Eli Lilly and Company, Lundbeck, Merck, Meso Scale Discovery (MSD), Pfizer, Piramal Enterprises, Ltd, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily and Voyager Therapeutics. OpenNeuro Japan: This data was obtained from the OpenfMRI database. Its accession number is ds000245. This research was supported in part by the following: a Grant-in-Aid from the Research Committee of Central Nervous System Degenerative Diseases by the Ministry of Health, Labour, and Welfare, Integrated Research on Neuropsychiatric Disorders project, carried out by SRBPS; a Grant-in-Aid for Scientific Research on Innovative Areas (Brain Protein Aging and Dementia Control 26117002) from the MEXT of Japan; Integrated Research on Neuropsychiatric Disorders carried out under the Strategic Research Program for Brain Sciences, Scientific Research on Innovative Areas (Comprehensive Brain Science Network); and Integrated Research on Depression, Dementia, and Development Disorders by the Strategic Research Program for Brain Sciences from the Japan Agency for Medical Research and Development (AMED). NEUROCON: This work was partially supported by the NEUROCON project (84/2012), financed by UEFISCDI. Stanford: This work was supported by the NIH/NINDS (K23 NS075097) and the Michael J Fox Foundation for Parkinson's Research. Oxford DISCOVERY: This work was funded by Parkinson's UK, NIHR Oxford Health Biomedical Research Centre. Amsterdam I: Grant support (not for this study) from the Netherlands Organisation for Health Research and Development, the Michael J Fox Foundation and the Hersenstichting. Amsterdam II (Cogtips): Cogtips is supported by the Dutch Parkinson's Disease Association ('Parkinson Vereniging' 19-2015) and Brain Foundation of the Netherlands ('Hersenstichting' HA-2017-00227). Liege Cohort: This work was funded by PDR Grant T0.165.14, National Fund for Scientific Research (FNRS), Belgium. Donders: This work was funded by a grant of the Dutch Brain Foundation (grant F2013(10-15 to R.H.), from the Netherlands Organization for Scientific Research (VENI grant #91617077), and from the Michael J Fox Foundation. Rome SLF: This work was funded by the Italian Ministry of Health, Italian Ministry of Health RC12-13-14-15-16-17-18-19/A. UNICAMP: This work was funded by the São Paulo Research Foundation FAPESP-BRAINN (2013-07559-3). PDNZ: This work was supported by the Health Research Council of New Zealand, Canterbury Medical Research Foundation, Neurological Foundation of New Zealand, University of Otago Research Grant, Brain Research New Zealand. Charlottesville: This work was supported by grants from Department of Defense, Commonwealth of Virginia's Alzheimer's and Related Diseases Research Award Fund, and University of Virginia. NW-England I & II: This work was funded by the Sydney Driscoll Neuroscience Foundation, University of Manchester Biomedical Imaging Institute, Medical Research Council UK Doctoral Training Programme, Engineering and Physical Science Research Council UK (EP/M005909/1). BE I & II: Co-author for the Bern cohort receives a grant from Boston Scientific. UDALL & U19 Cohort: This work was funded by the NINDS, NIH AG062418 (U19) and NS053488 (P50). We would like to acknowledge the support of Alice Chen Plotkin for MRI and clinical data collection. CGU: This work was supported by MOST 106-2314-B-182-018-MY3, EMRPD1K0451, EMRPD1K0481. Schol-AR: Support for this work was provided by the National Institutes of Health (grants P41EB015922 and U54EB020406) and by the Michael J. Fox Foundation's Parkinson's Progression Markers Initiative (PPMI – award # 8283.03).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵∇ These authors share the first authorship on this manuscript.
Data Availability
Data are not publicly available except for the OpenNeuro Japan, Tao Wu & Neurocon, and Parkinson's Progression Markers Initiative (PPMI) datasets.
http://fcon_1000.projects.nitrc.org/indi/retro/parkinsons.html
